38.47 USD
▲+0.90+2.40%
盘后 39.10 +1.64%
2026-09-15
市值
$1.39B
市盈率
—
EPS
-4.53
股息率
—
52 周区间
14.72 – 49.91
成交量
526.05K
Beta
—
目标价
69.44
52W 低 14.7252W 高 49.91
价格走势
公司简介
First Tracks Biotherapeutics, Inc. operates a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases in United States. Its products includes ANB033, a novel anti‑CD122 antagonist that targets the shared beta subunit of the IL‑15 and IL‑2 receptors; Rosnilimab, a antibody engineered to selectively deplete pathogenic T cells in both the periphery and inflamed tissues; and ANB101, a BDCA2‑modulating antibody designed to specifically target plasmacytoid dendritic cells (pDCs). Fir...